Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Vivani Medical received ethics committee approval in Australia to initiate SLIM-1, a Phase 1 trial of its semaglutide implant NPM-139. The randomized, active-controlled study will evaluate safety, tolerability, and pharmacokinetics against Wegovy over a four-week period in obese subjects.
Key figures
- Drug Name
- NPM-139
- Phase Of Trial
- Phase 1
- Trial name
- SLIM-1
- Duration weeks
- 4
- Subjects per group
- 10
- Comparator dose mg per week
- 0.25
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.